

Resource Summary Report

Generated by [ASWG](#) on Aug 3, 2026

ELDA

RRID:SCR_018933

Type: Tool

Proper Citation

ELDA (RRID:SCR_018933)

Resource Information

URL: <http://bioinf.wehi.edu.au/software/elda/>

Proper Citation: ELDA (RRID:SCR_018933)

Description: Software tool for limiting dilution analysis, with particular attention to needs of stem cell assays. Provides confidence intervals for all LDA data sets, including those with 0% or 100% responses. Other features include test of adequacy of single hit hypothesis, tests for frequency differences between multiple data sets, and ability to take advantage of cases where number of cells in sample is counted exactly.

Synonyms: Extreme Limiting Dilution Analysis

Resource Type: software resource, production service resource, data processing software, service resource, software application, data analysis software, analysis service resource

Defining Citation: [PMID:19567251](#)

Keywords: Limiting dilution analysis, stem cell assay, data set confidence intervals, single hit hypothesis, adequacy test, frequency differences test

Availability: Free, Freely available

Resource Name: ELDA

Resource ID: SCR_018933

Record Creation Time: 20220129T080342+0000

Record Last Update: 20260803T040754+0000

Ratings and Alerts

No rating or validation information has been found for ELDA.

No alerts have been found for ELDA.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 385 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Chen K, et al. (2026) Liquid-liquid phase separation of PHLDB2 promotes oral squamous cell carcinoma metastasis through regulating epithelial mesenchymal transition and PIK3CA expression. *Molecular medicine reports*, 33(1).

Su J, et al. (2026) TAF1 acetyltransferase promotes colorectal carcinoma metastasis by catalyzing γ -hydroxybutyrylation of KCTD9. *Oncogene*, 45(1), 87.

Daley BR, et al. (2025) SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. *Cancer research*, 85(1), 118.

Doroszko M, et al. (2025) The invasion phenotypes of glioblastoma depend on plastic and reprogrammable cell states. *Nature communications*, 16(1), 6662.

Lv M, et al. (2025) SIRT4 Promotes Pancreatic Cancer Stemness by Enhancing Histone Lactylation and Epigenetic Reprogramming Stimulated by Calcium Signaling. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(20), e2412553.

Jang HL, et al. (2025) L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. *Scientific reports*, 15(1), 22705.

Veo B, et al. (2025) Single-cell multi-omics identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma. *Nature communications*, 16(1), 10470.

Jang TY, et al. (2025) Dysadherin/YAP axis fuels stem plasticity and immune escape in liver cancer. *Signal transduction and targeted therapy*, 10(1), 421.

Wu Y, et al. (2025) Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma. *Scientific reports*, 15(1), 954.

Yang YC, et al. (2025) GNE-317 Reverses MSN-Mediated Proneural-to-Mesenchymal Transition and Suppresses Chemoradiotherapy Resistance in Glioblastoma via PI3K/mTOR. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(12), e2412517.

Li X, et al. (2025) CircMAN1A2 Levels Determine GBM Susceptibility to TMZ in a Pathway Involving TEP1- and KEAP1-Mediated NRF2 Degradation Leading to Ferroptosis. *CNS neuroscience & therapeutics*, 31(7), e70489.

Wang K, et al. (2025) ALKBH5 Promotes Breast Cancer Stemness Through Regulating Wnt/ β -Catenin Signaling. *Breast cancer* (Dove Medical Press), 17, 471.

Yang Y, et al. (2025) SOX4-ZIP14-zinc metabolism mediates oncogenesis and suppresses T cell immunity in nasopharyngeal carcinoma. *Cell reports. Medicine*, 6(9), 102300.

Korleski J, et al. (2025) Multipronged SMAD pathway targeting by lipophilic poly(β -amino ester) miR-590-3p nanomiRs inhibits mesenchymal glioblastoma growth and prolongs survival. *Signal transduction and targeted therapy*, 10(1), 145.

Lyu X, et al. (2025) Impact of LIN7A silencing on U87 cell invasion and its clinical significance in glioblastoma. *Scientific reports*, 15(1), 7212.

Yan B, et al. (2025) CD146 regulates the stemness and chemoresistance of hepatocellular carcinoma via JAG2-NOTCH signaling. *Cell death & disease*, 16(1), 150.

Liu X, et al. (2025) PHGDH activation fuels glioblastoma progression and radioresistance via serine synthesis pathway. *Journal of experimental & clinical cancer research : CR*, 44(1), 99.

Lu C, et al. (2025) Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression. *Nature communications*, 16(1), 2974.

Wang Y, et al. (2025) Chromatin Organization Governs Transcriptional Response and Plasticity of Cancer Stem Cells. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(17), e2407426.

Talukdar PD, et al. (2025) Precise targeting of transcriptional co-activators YAP/TAZ annihilates chemoresistant brCSCs by alteration of their mitochondrial homeostasis. *Signal transduction and targeted therapy*, 10(1), 61.